Dyve Biosciences
Dyve Biosciences leverages its DMAX transdermal platform to deliver pH modulation for treating immunologic and oncologic diseases, with lead products DYV800 and DYV700 targeting acidic microenvironments.
Company Overview
Dyve Biosciences utilizes the DMAX transdermal platform to deliver pH modulation for treating immunologic and oncologic diseases. The company's innovative approach targets acidic microenvironments in these health areas to address various diseases effectively. Their leading products, DYV800 and DYV700, are designed to modulate pH levels, offering new treatment possibilities where traditional methods may be ineffective.
Products
Dyve Biosciences' lead products include DYV800 and DYV700. DYV800 aims to raise the pH of acidic tumor microenvironments to inhibit tumor proliferation, while DYV700 is pivotal-trial ready for treating acute gout. Additionally, DYV024 is in the preclinical stage for the treatment of psoriasis. The company’s DMAX platform enables these products to be delivered transdermally, providing an alternative to oral or injectable delivery methods.
Research and Development
Dyve Biosciences announced a research and development collaboration with Moffitt Cancer Center in February 2022. The company presented preclinical data for DYV800 at the American Association for Cancer Research 2023 Annual Meeting and hosted a key opinion leader webinar on gout and DYV702 in November 2021. Other significant presentations include the 34th Annual Roth Conference and the UBS Global Healthcare Conference in 2022.
Clinical Trials
Dyve Biosciences completed a successful phase 2 study in 2022 for DYV700, targeting pain reduction in acute gouty arthritis. The company received FDA clearance in December 2019 to begin a Phase 2 study of DYV700 for acute gout pain. Dyve Biosciences also announced positive results from a pilot study in gout pain at the European Crystal Network Workshop 2019.
Industry Participation
Dyve Biosciences actively participates in industry events to showcase their developments and expand collaborations. The company participated in the BIO International Convention in June 2022 and presented at several conferences, including the Biocom California Global Life Science Partnering Conference in February 2022 and the UBS Global Healthcare Conference in May 2022.